ImmuPharma PLC (AIM:IMM, OTC:IMMPF) plans to focus this year on advancing Lupuzor, its lupus treatment, into phase II/III clinical trials later in the year.
Immupharma PLC (LON:IMM) Update on Corporate Activities
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to provide an update on ongoing activities.